A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
Clinical trial NCT05335941 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05335941
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-13
- Primary completion
- 2027-09-30
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.